Eric C. Hsu
Sr. VP, Pre-Clinical Res/Dev · InMed Pharmaceuticals Inc.
Individual
- 2024
- Dec 19, 2025
- 3
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Eric C. Hsu files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ADAR1 Capital Management, LLC - $913K in INM purchases and sales in the last 12 months
- Vivo Opportunity, LLC - $434K in INM purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Eric C. Hsu?
Eric C. Hsu is a corporate insider, tracked as Sr. VP, Pre-Clinical Res/Dev of InMed Pharmaceuticals Inc. (INM). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Eric C. Hsu last file a Form 4?
The most recent primary Form 4 on record is dated 19 December 2025, one of 3 filings going back to 2024.